Notably, CAV2 deficiency synergized with Cetuximab treatment, reducing the the half maximal inhibitory concentration (IC<sub>50</sub>) value by 6-fold compared with control cells and suppressing tumor growth by 48.41% in xenograft models compared to Cetuximab monotherapy (<i>p</i> < 0.0001). The gene discussed is CAV2; the disease is neoplasm.